Letters Faulty device and rivaroxaban

Optimal dosing of rivaroxaban is undefined

BMJ 2016; 355 doi: https://doi.org/10.1136/bmj.i5549 (Published 18 October 2016) Cite this as: BMJ 2016;355:i5549
  1. Thomas J Moore, senior scientist
  1. Institute for Safe Medication Practices, 101 N Columbus St, Suite 410, Alexandria, VA 22314, USA
  1. tmoore{at}ismp.org

The faulty INRatio device used in the rivaroxaban ROCKET atrial fibrillation trial1 is particularly important in light of another drawback to this novel oral anticoagulant (NOAC). Rivaroxaban has the shortest terminal half life of the …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe